Literature DB >> 21812917

Association of serum uric acid with graft survival after kidney transplantation: a time-varying analysis.

A Haririan1, M Metireddy, C Cangro, J M Nogueira, F Rasetto, M Cooper, D K Klassen, M R Weir.   

Abstract

The association of serum uric acid (UA) with kidney transplant outcomes is uncertain. We examined the predictive value of UA during the first year posttransplant as a time-varying factor for graft survival after adjustment for time-dependent and independent confounding factors. Four hundred and eighty-eight renal allograft recipients transplanted from January 2004 to June 2006 and followed for 41.1 ± 17.7 months were included. Data on UA, estimated glomerular filtration rate (eGFR), tacrolimus level, mycophenolate mofetil (MMF) and prednisone doses, use of allopurinol, angiotensin-converting enzyme-inhibitor/angiotensin-receptor-blocker (ACEi/ARB) and diuretics at 1, 3, 6, 9 and 12 months were collected. Primary endpoint of the study was graft loss, defined as graft failure and death. Cox proportional hazard models and generalized estimating equations were used for analysis. UA level was associated with eGFR, gender, retransplantation, decease-donor organ, delayed graft function, diuretics, ACEi/ARB and MMF dose. After adjustment for these confounders, UA was independently associated with increased risk of graft loss (HR: 1.15, p = 0.003; 95% CI: 1.05-1.27). Interestingly, UA interacted with eGFR (HR: 0.996, p < 0.05; 95% CI: 0.993-0.999 for interaction term). Here, we report a significant association between serum UA during first year posttransplant and graft loss, after adjustment for corresponding values of time-varying variables including eGFR, immunosuppressive drug regimen and other confounding factors. Its negative impact seems to be worse with lower eGFR. © 2011 The Authors Journal compilation © 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21812917     DOI: 10.1111/j.1600-6143.2011.03613.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

1.  The effects of mammalian target of rapamycin inhibitors on serum uric acid levels in renal transplant patients.

Authors:  Ozkan Gungor; Mehmet Tanrisev; Fatih Kircelli; Mehmet Nuri Turan; Cem Tugmen; Erhan Tatar; Huseyin Toz
Journal:  Int Urol Nephrol       Date:  2012-06-30       Impact factor: 2.370

2.  New-Onset Gout as an Independent Risk Factor for Returning to Dialysis After Kidney Transplantation.

Authors:  Justin W Li; David Yin; Zheng Wang; Mark D Brigham; Brian D LaMoreaux; Jeffrey D Kent; Megan Francis-Sedlak; Richard J Johnson; Nandini Hadker; Kevin M Francis; Herman A Sanchez; Gavin Miyasato
Journal:  Transplant Direct       Date:  2020-11-16

Review 3.  Inflammatory triggers of acute rejection of organ allografts.

Authors:  Daniel N Mori; Daniel Kreisel; James N Fullerton; Derek W Gilroy; Daniel R Goldstein
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

4.  Serum Uric Acid and Risk of CKD in Type 2 Diabetes.

Authors:  Salvatore De Cosmo; Francesca Viazzi; Antonio Pacilli; Carlo Giorda; Antonio Ceriello; Sandro Gentile; Giuseppina Russo; Maria C Rossi; Antonio Nicolucci; Pietro Guida; Daniel Feig; Richard J Johnson; Roberto Pontremoli
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-04       Impact factor: 8.237

Review 5.  Effects of hyperuricemia on renal function of renal transplant recipients: a systematic review and meta-analysis of cohort studies.

Authors:  Yan Huang; Yu-Lin Li; He Huang; Ling Wang; Wen-Ming Yuan; Jing Li
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

6.  Serum Uric Acid and Renal Transplantation Outcomes: At Least 3-Year Post-transplant Retrospective Multivariate Analysis.

Authors:  Kun Zhang; Baoshan Gao; Yuantao Wang; Gang Wang; Weigang Wang; Yaxiang Zhu; Liyu Yao; Yiming Gu; Mo Chen; Honglan Zhou; Yaowen Fu
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

7.  Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.

Authors:  Tadashi Sofue; Masashi Inui; Taiga Hara; Yoko Nishijima; Kumiko Moriwaki; Yushi Hayashida; Nobufumi Ueda; Akira Nishiyama; Yoshiyuki Kakehi; Masakazu Kohno
Journal:  Drug Des Devel Ther       Date:  2014-02-17       Impact factor: 4.162

8.  Association between post-transplant uric acid level and renal allograft fibrosis: Analysis using Banff pathologic scores from renal biopsies.

Authors:  Deok Gie Kim; Beom Seok Kim; Hoon Young Choi; Beom Jin Lim; Kyu Ha Huh; Myoung Soo Kim; Hyeon Joo Jeong; Yu Seun Kim
Journal:  Sci Rep       Date:  2018-08-02       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.